 |
 |
 |
|
 |
articles < press << main |
 |
 |
|
|
|
|
|
|
|
| date | | | | title / topic / summary | sort by topic |
|---|
|
| 08/03/2005 | | | | Tobacco Smoke Exposure for Teens Linked to Obesity and Higher Risk of Cardiovascular Disease and Diabetes
topic: Tobacco Exposure Tests
August 3, 2005: A new study has linked exposure to second-hand
smoke by teen-agers to metabolic syndrome, a condition associated with obesity and with increased risk of cardiovascular disease, such as stroke and heart attack, and Type II diabetes. |
| 08/02/2005 | | | | Second-Hand Smoke Exposure During Pregnancy Puts Fetus at Risk According to New Study
topic: Tobacco Exposure Tests
August 2, 2005: Exposure
to second-hand smoke during pregnancy can be as harmful to an unborn child as maternal smoking, according to a new study. |
| 07/26/2005 | | | | Nymox Expands Its Issued Patent Position for E. Coli Treatments
topic: R&D: E coli and Other Antibacterial Treatments
July 26, 2005: Nymox announced today that the Company has received a Notice of Allowance of a new U.S. patent
covering a wide range of uses of its anti-bacterial treatments both in animals and in man. |
| 07/20/2005 | | | | New Coverage of Nymox Initiated by Cohen Independent Research Group
topic: Financial
July 20, 2005: Nymox announced
today that Cohen Independent Research Group has initiated research coverage of the Company. |
| 07/18/2005 | | | | FDA Panel Votes 5-2 Against Kit Form of NTP Test
topic: AlzheimAlert™ & Diagnosis of Alzheimer's Disease
July 18, 2005: Nymox announced
today that on Friday, July 15, an FDA advisory panel voted 5-2 against approval of the kit
form of the Company's NTP test (AlzheimAlert™). AlzheimAlert™ remains approved
for sale in the U.S. as a laboratory testing service through the Company's clinical
reference laboratory in New Jersey. |
| 07/11/2005 | | | | Evidence and Acceptance Grows For Taking Statin Drugs to Treat Dementia
topic: Statins and Alzheimer's Disease
July 11, 2005: Nymox's U.S. and
global patent rights and prospects for the use of statin drugs for treating, preventing or
reducing the risk of Alzheimer's disease (AD) in patients at risk for the disease have been supported by growing scientific evidence and acceptance by doctors. |
| 07/08/2005 | | | | Nymox Moves Forward With Global Marketing Agreements For Company's Proprietary AlzheimAlert™ Test
topic: AlzheimAlert™ & Diagnosis of Alzheimer's Disease
July 8, 2005: Nymox continues to
make major progress in the global marketing strategy for the Company's unique urine
testing technology for Alzheimer's disease (AD). The Company now has attained CLIA approval in the U.S., and the CE Mark in Europe. The Company recently
announced distribution and marketing agreements for Italy with Alifax S.p.A., for the
Czech Republic with KlinLab Inc., and for Greece with B. Carivitis S.A. |
| 07/07/2005 | | | | Nymox NX-1207 For Benign Prostatic Hyperplasia Shows Promise For Common Problem
topic: R&D: BPH (enlarged prostate) Treatments
July 7, 2005: Nymox reported
today that its lead drug candidate NX-1207 for the treatment of benign prostatic
hyperplasia (BPH) shows good promise as a potential first-line treatment for BPH. In two
completed trials in the U.S. to date, the drug has shown highly significant efficacy
without significant side effects. The Company's large Phase 2 trial is expected to be
completed later this year. |
| 07/05/2005 | | | | Nymox Signs Marketing and Distribution Deal for AlzheimAlert™ Kit in Greece
topic: AlzheimAlert™ & Diagnosis of Alzheimer's Disease
July 5, 2005: Nymox announced
today that it has entered into an agreement with B. Caravitis S.A. for the marketing and
sales of Nymox's AlzheimAlert™ product in Greece. |
| 06/29/2005 | | | | Exposure to Mother's Smoke Increases Risk of Asthma in Adults According to New Study
topic: Tobacco Exposure Tests
June 29, 2005: Childhood exposure to mother's second hand smoke
substantially increases the risk for developing adult asthma and other respiratory
symptoms according to a new paper published in the current issue of the American
Journal of Respiratory and Critical Care Medicine. Nymox makes TobacAlert™, an easy-to-use,
cost-effective product that allows for on-site testing for second-hand smoke exposure. |
|